Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics

Therapeutic Drug Monitoring

Volumn 31, Issue 6, 2009, Pages 764-768

  Yamada, Satoshi ^a   Yasui Furukori, Norio ^b   Akamine, Yumiko ^a   Kaneko, Sunao ^b   Uno, Tsukasa ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Carbamazepine; Fexofenadine; P glycoprotein; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; FEXOFENADINE; GLYCOPROTEIN P;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; P-GLYCOPROTEIN; TERFENADINE; YOUNG ADULT;

EID: 73849094765     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181bf7db6     Document Type: Article

References (40)

1. Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55:425-461.
2. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 2001;31:469-497.
3. Kim RB. Transporters and xenobiotic disposition. Toxicology. 2002;181-182:291-297.
4. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003;42:59-98.
5. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest. 2003;33:6-9.
6. Balayssac D, Authier N, Cayre A, et al. Does inhibition of Pglycoprotein lead to drug-drug interactions? Toxicol Lett. 2005;156:319-329
7. Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999;27:866-871.
8. Putnam WS, Ramanathan S, Pan L, et al. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci. 2002;91:2622-2635.
9. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol. 2002;42:1269-1274.
10. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002;53:526-534.
11. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs. 2000; 59:301-321.
12. Niemi M, Kivisto KT, Hofmann U, et al. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol. 2005;59:602-604. (Pubitemid 40632253)
13. Shimizu M, Fuse K, Okudaira K, et al. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005;33:1477-1481.
14. Nozawa T, Imai K, Nezu J, et al. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in humans. J Pharmacol Exp Ther. 2004;308:438-445.
15. Shon JH, Yoon YR, Hong WS, et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005;78:191-201.
16. Shimizu M, Uno T, Sugawara K, et al. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol. 2006;61:538-544.
17. Shimizu M, Uno T, Sugawara K, et al. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol. 2006;62:372-376.
18. Uno T, Shimizu M, Sugawara K, et al. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos. 2006;34:1875-1879.
19. Yasui-Furukori N, Uno T, Sugawara K, et al. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77:17-23.
20. Otani K, Yasui N, Kaneko S, et al. Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int Clin Psychopharmacol. 1996;11:55-57.
21. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. Clin Pharmacokinet. 1986;11:177-198.
22. Pirmohamed M, Allott R, Green VJ, et al. Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. Br J Clin Pharmacol. 1994;37:577-581.
23. Wietholtz H, Zysset T, Kreiten K, et al. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol. 1989;36:401-406.
24. Yue QY, Tomson T, Säwe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man.Pharmacogenetics. 1994; 4:193-198.
25. Owen A, Goldring C, Morgan P, et al. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol. 2006;62:237-242.
26. Yang HW, Liu HY, Liu X, et al. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci Lett. 2008;434: 299-303.
27. Lü Y, Yan Y, Wang XF. Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. Chin Med J (Engl). 2004;117:1682-1686.
28. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001; 276:14581-14587.
29. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76:192-200.
30. Lombardo L, Pellitteri R, Balazy M, et al. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res. 2008;5:82-92.
31. Uno T, Yasui-Furukori N, Takahata T, et al. Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection. J Pharm Biomed Anal. 2004;35:937-942.
32. Hamman MA, Bruce MA, Haehner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther. 2001;69:114-121.
33. Dresser GK, Schwarz UI, Wilkinson GR, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther. 2003;73:41-50.
34. Asghar A, Gorski JC, Haehner-Daniels B, et al. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos. 2002;30:20-26.
35. Dürr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598-604.
36. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A. 2000;97:7500-7502.
37. Tirona RG, Leake BF, Wolkoff AW, et al. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003; 304:223-228.
38. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single-and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther. 1998;64:612-621.
39. Tian X, Zamek-Gliszczynski MJ, Li J, et al. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos. 2008;36:61-64.
40. Gerk PM, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharmacol Exp Ther. 2002;302:407-415.